Every 10-Q that Stereotaxis, Inc. (STXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STXS filings page.
Stereotaxis, Inc. reported lower sales and higher losses for the six months ended June 30, 2026. Total revenue was $13.96 million, down from $16.27 million a year earlier, as systems revenue declined to $2.80 million from $5.00 million, while disposables, service and accessories were roughly flat at $11.16 million.
Gross margin was $8.28 million versus $8.64 million, but operating expenses rose slightly to $18.83 million, driving an operating loss of $10.55 million and a net loss of $10.33 million (net loss attributable to common stockholders $10.95 million). Cash used in operating activities was $7.12 million in the first half.
Cash and cash equivalents were $10.49 million at June 30, 2026, down from $13.42 million at year-end, partly offset by $5.3 million of net proceeds from an at-the-market equity program. The company continues to accumulate deficits (accumulated deficit $593.7 million) and expects additional losses as it invests in R&D, commercialization, and newly acquired operations.
Strategically, Stereotaxis is transitioning from third-party J&J catheters to its own MAGiC ablation catheter, which received FDA 510(k) clearance in January 2026, and advancing the MAGiC Sweep mapping catheter, cleared in July 2025. On July 7, 2026, it closed the acquisition of Robocath for roughly $20 million in cash and stock, with up to $25 million in potential earnouts, expanding into mechanical robotics for interventional cardiology and neurointerventions.
Stereotaxis, Inc. reported a Q1 2026 net loss of $5.9M, similar to the prior year, as it continues investing in robotic cardiac and endovascular technologies. Revenue declined to $6.3M from $7.5M, with lower systems and disposable sales partly offset by higher service and accessories.
Operating expenses were $9.8M, roughly flat year over year, and basic and diluted net loss per share improved slightly to $0.06 from $0.07. Cash, cash equivalents, and restricted cash increased to $14.6M at March 31, 2026, helped by net proceeds of about $4.6M from an at-the-market stock offering.
The company signed an agreement on April 14, 2026 to acquire Robocath for $20.0M in cash and/or stock plus up to $25.0M in milestone-based contingent consideration, aiming to add mechanical robotic technology for interventional cardiology and neurointerventions. Stereotaxis also continues ramping its MAGiC and MAGiC Sweep catheters and faces macroeconomic, tariff, supply chain, and hospital capital spending headwinds while carrying an accumulated deficit of about $589.2M.
Stereotaxis (STXS) reported Q3 2025 results. Revenue was $7.5 million, down from $9.2 million a year ago, as systems sales softened while disposables, service and accessories grew. Systems revenue was $1.9 million versus $4.4 million, and disposables, service and accessories reached $5.6 million versus $4.8 million.
Gross margin was $4.1 million, roughly flat year over year, while operating loss was $6.6 million versus $6.3 million. Net loss was $6.5 million compared with $6.2 million, and basic/diluted EPS was ($0.07) versus ($0.08). For the first nine months, revenue rose to $23.7 million from $20.6 million, reflecting stronger recurring revenue. Cash and cash equivalents were $10.5 million at September 30, 2025. Deferred revenue totaled $8.1 million, supporting future service and delivery obligations.
The company continued integrating Access Point Technologies (APT), which contributed $4.1 million in revenue for the nine months. Stereotaxis established a $50.0 million at‑the‑market program on August 29, 2025, with no shares issued under it through quarter-end. Shares outstanding were 93,324,763 as of October 31, 2025.
Stereotaxis, Inc. reported stronger top-line results for the quarter ended June 30, 2025, with total revenue of $8.8 million, up from $4.5 million a year earlier, and $16.3 million for the six months versus $11.4 million in 2024. Growth was driven by higher systems sales ($3.0 million in Q2 2025 versus $0.24 million) and increased disposables, service and accessories revenue. Gross margin improved to $4.6 million in the quarter from $3.3 million a year ago, and operating loss narrowed to $4.0 million from $6.0 million in the prior-year quarter.
Despite improved operating performance, the company remains unprofitable with a six-month net loss of $9.6 million and a cumulative deficit of approximately $571.4 million. Cash and cash equivalents were $6.97 million at June 30, 2025, and operating cash used was $5.5 million for the six months. The company completed an earlier acquisition of Access Point Technologies (APT), recognized related intangible assets and goodwill, recorded a $0.5 million contingent consideration revaluation charge, and disclosed a July 2025 registered offering with initial gross proceeds of $8.5 million and $4.0 million expected at a later closing.